Elite Pharmaceuticals Total Liabilities

Elite Pharmaceuticals (ELTP) currently reports a total liabilities of $22B as of March 2026. That compares with $43M in the prior-year period — up 51250.9% year over year. Use the charts on this page to explore Elite Pharmaceuticals's total liabilities history and peer comparisons.

Elite Pharmaceuticals's total liabilities increased from $43M to $22B — a 51250.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Elite Pharmaceuticals reported $22B in total liabilities as of March 2026. That compares with $43M in the prior-year period — up 51250.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $22B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Elite Pharmaceuticals, and consider following ELTP for alerts when major investors trade the stock.

Elite Pharmaceuticals is classified in the Healthcare sector. On total liabilities, it currently shows $22B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ELTP with unrelated industries.